Alice Mims
Beat AML · Ohio State University Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alice Mims as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:10 UTC. Open this list on ClinicalTrials.gov
- Ph2/Ph3NCT03013998 · Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaBeat AML, LLC · recruiting · Previously Untreated Relapsed Refractory Acute Myeloid Leukemia · principal investigator
- Ph1NCT02299518 · Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaAlice Mims · completed · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) · principal investigator
- Ph1NCT01130506 · Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeNational Cancer Institute (NCI) · completed · Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Dual Targeting of Oncogenic Signaling and Immune Suppression in High-Risk T-ALLR01CA317674 · NCI · OHIO STATE UNIVERSITY · fiscal years 2026 · $511,944 awarded in 2026Same name and institution; not confirmed by an ID
- Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AMLR01CA262496 · NCI · OHIO STATE UNIVERSITY · fiscal years 2022 to 2026 · $651,938 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting NAMPT in Acute Myeloid LeukemiaR01CA223165 · NCI · OHIO STATE UNIVERSITY · fiscal years 2018 to 2022 · $461,498 awarded in 2022Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Shared Resource 10: Pharmacoanalytical Shared Resource (PhASR)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Mitch A Phelps · fiscal years 2013 to 2026Named on NCT01130506
- U01CA076576RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01130506
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:10 UTC. The ranking covers the 200 most relevant of 28 PubMed records, and a shared surname and initials can bring in a namesake. All 28 on PubMed
- 1,254 citationsRCR 40.6
- 318 citationsRCR 12.5
- 198 citationsRCR 10.5
- 151 citationsRCR 5.5
- Web-based weight management programs in an integrated health care setting: a randomized, controlled trial.Obesity (Silver Spring) · 2006127 citationsRCR 4.5
- 120 citationsRCR 2.9
- Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.Blood Adv · 202261 citationsRCR 4.6
- Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.J Clin Oncol · 202558 citationsRCR 13.6
- Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.Clin Cancer Res · 202353 citationsRCR 5.1
- Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.Blood Adv · 201852 citationsRCR 1.9